

7 Literaturverzeichnis

- ¹ Kerner W, Brückel J, Böhm BO: Definition, Klassifikation und Diagnostik des Diabetes mellitus. Aktualisierte Version auf den Webseiten der DDG „www.deutsche-diabetes-gesellschaft.de“/Evidenzbasierte Leitlinien/Definition. November 2004
- ² American Diabetes Association: American Diabetes Association: Diagnosis and Classification of Diabetes Mellitus, Diabetes Care, 2006; 29: S43-S48
- ³ Pfeifer MA, Halter JB, Porte D Jr: Insulin secretion in diabetes mellitus. Am J Med, 1981; 70: 579-588
- ⁴ Rothman DL, Magnusson I, Katz LD et al.: Quantitation of hepatic glycogenolysis in fasting human with ¹³C NMR. Science, 1991; 254: 573-576
- ⁵ Häring HU, Joost HG, Laube H et al.: Antihyperglykämische Therapie des Diabetes mellitus Typ 2. in: Evidenzbasierte Diabetes-Leitlinie DDG. Scherbaum WA, Landgraf R (Hrsg) Diabetes und Stoffwechsel, 2003; 12: Suppl 2
- ⁶ Mühlhauser I: Hypoglykämie. in: Diabetes mellitus, Berger M (Hrsg), 2. Auflage 2000, Urban & Fischer Verlag, München, Jena
- ⁷ Cryer PE, Frier BM: Hypoglycaemia. in: International Textbook of Diabetes Mellitus, Alberti KGMM, Zimmet P, DeFronzo RA, Keen H (Hrsg), 2. Auflage 1997, John Wiley & Sons Ltd; Chicester , England
- ⁸ Mitrakou A, Ryan C, Veneman T et al.: Hierachy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol, 1991; 260: E67-74
- ⁹ Schwartz NS, Clutter WE, Shah SD, Cryer PE: Glycemic thresholds for activation of glucose counterregulatory systems are higher than the thresholds for symptoms. J Clin Invest, 1987; 79: 777-781

- ¹⁰ Nagy R, O'Connor A, Boyle PJ: Modest hypoglycemia impairs brain glucose utilization before onset of symptoms. *Diabetes*, 1992; 41: 69A
- ¹¹ Heller SR, Cryer PE: Reduced neuroendocrine and sympathomatic responses to subsequent hypoglycemia after one episode of hypoglycemia in nondiabetic humans. *Diabetes*, 1991; 40: 223-226
- ¹² Cryer PE: Glucose counterregulation: Prevention and correction of hypoglycemia in humans. *Am J Physiol*, 1993; 264: E149-155
- ¹³ Hatz HJ: *Glucocorticoide*, 2005, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart
- ¹⁴ Thomas L (Hrsg.) *Labor und Diagnose*. 4. Auflage 1995, Die Medizinische Verlagsgesellschaft, Marburg
- ¹⁵ Mc Mahon M, Gerich J, Rizza R: Effects of glucocorticoids on carbohydrate metabolism. *Diabetes Metab Rev*, 1988; 4: 17-30
- ¹⁶ Bressler P, DeFronzo RA: Drug effects on glucose homeostasis. in: *International Textbook of Diabetes Mellitus*, Alberti KGMM, Zimmet P, DeFronzo RA, Keen H (Hrsg), 2. Auflage 1997, John Wiley & Sons Ltd; Chicester , England
- ¹⁷ Shamon H, Soman V, Sherwin RS: The influence of acute physiological increments of cortisol on fuel metabolism and insulin binding to monocytes in normal humans. *J Clin Endocrinol Metab*, 1980; 50: 495-501
- ¹⁸ DeFeo P, Perriello G, Torlone E et al.: Contribution of cortisol to glucose counterregulation in humans. *Am J Physiol*, 1989; 257: E35-42
- ¹⁹ Meneilly GS, Cheung E, Tuokko H: Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. *Diabetes*, 1994; 43: 403-410

- ²⁰ Fanelli C, Pampanelli S, Calderone S et al.: Effects of recent short term hyperglycemia on responses to hypoglycemia in humans. *Diabetes*, 1995; 44: 513-519
- ²¹ Caron MG, Lefkowitz RJ: Catecholamine receptors. Structure, function and regulation. *Recent Prog Horm Res*, 1993; 48: 277
- ²² Ruffolo RR Jr, Hieble JP: α -Adrenoreceptors. *Pharmacol Ther*, 1994; 61: 1
- ²³ Nakadate T, Nakaki T, Muraki T, Kato R: Adrenergic regulation of blood glucose levels: possible involvement of postsynaptic alpha2-type adrenergic receptors regulating insulin release. *J Pharmacol Exp Ther*, 1980; 215: 226-230
- ²⁴ Clutter WE, Rizza RA, Gerich JE, Cryer PE: Regulation of glucose metabolism by sympathochromaffin catecholamins. *Diabetes Metab Rev*, 1988; 4: 1-15
- ²⁵ Davis SN, Shavers C, Collins L, Cherrington AD, Price L, Hedstrom C: Effects of physiological hyperinsulinemia on counterregulatory response to prolonged hypoglycemia in normal humans. *Am J Physiol*, 1994; 267: E402-E410
- ²⁶ Meneilly GS, Cheung E, Tuokko H: Altered responses to hypoglycemia of healthy elderly people. *J Clin Endocrinol Metab*, 1994; 78: 1341-1348
- ²⁷ Koop I, Preuss P, Löffler C, Will S, Fußgänger P, Jehle P: Insulin receptor downregulation during hypoglycemia. *Diabetes*, 1997; 46 (Suppl.1) 103A
- ²⁸ Kahn CR, White MF: The insulin receptor and the molecular mechanism of insulin action. *J Clin Invest*, 1988; 82: 1151-1154
- ²⁹ Olefsky JM: Perspectives in diabetes. The insulin receptor: a multifunctional protein. *Diabetes*, 1990; 39: 1009-1015
- ³⁰ Rosen OM: Banting Lecture. Structure and function of insulin receptors. *Diabetes*, 1989; 38: 1508-1514

- ³¹ Carpentier JL: The cell biology of the insulin receptor. *Diabetologia*, 1989; 32: 627-663
- ³² Theis RS, Molina JM, Ciaraldi TP, Freidenberg JR, Olefsky JM: Insulin-receptor autophosphorylation and endogenous substrate phosphorylation in human adipocytes from control, obese and NIDDM subjects. *Diabetes*, 1990; 39: 250-258
- ³³ Caro JF, Sinha MK, Raju SM et al.: Insulin receptor kinase in human skeletal muscle from obese subjects with and without non-insulin-dependent diabetes. *J Clin Invest*, 1987; 79: 1330-1337
- ³⁴ Caro JF, Ittoop O, Pories WJ et al.: Studies on the mechanism of insulin resistance in the liver from humans with non insulin dependent diabetes, Insulin action and binding in isolated hepatocytes, insulin receptor structure, and kinase activity. *J Clin Invest*, 1986; 78: 249-258
- ³⁵ Bell GI: Lilly Lecture. Molecular defects in diabetes mellitus. *Diabetes*, 1990; 40: 413-422
- ³⁶ Saltiel AR: Second messengers of insulin action. *Diabetes Care*, 1990; 13: 244-253
- ³⁷ Yu KT, Khalaf N, Czech MP: Insulin stimulates a membrane- bound serine kinase that may be phosphorylated on tyrosine. *Proc Natl Acad Sci USA*, 1987; 84: 3972-3976
- ³⁸ Lane MD, Flores-Riveros JR, Hresko RC et al.: Insulin-receptor tyrosine kinase and glucose transport. *Diabetes Care*, 1990; 13: 565-574
- ³⁹ Seino S, Seino M, Bell GI: Human insulin-receptor gene. *Diabetes*, 1990; 39: 129-132
- ⁴⁰ Taylor SI, Kadowaki T, Kadowaki H, Accili D, Cama A, McKeon C: Mutations in insulin-receptor gene in insulin-resistant patients. *Diabetes Care*, 1990; 13: 257-275

- ⁴¹ Kadowaki T, Kadowaki H, Rechler MM et al.: Five mutant alleles of the insulin receptor gene in patients with genetic forms of insulin resistance in NIDDM. *J Clin Invest*, 1990; 86: 254-262
- ⁴² Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A, McClain DE: Functionally distinct insulin receptors generated by tissue-specific alternative splicing. *EMBO J*, 1990; 9: 2409-2414
- ⁴³ Moller DE, Yokota A, Caro JF, Flier JS: Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. *Mol Endocrinol*; 1989; 3: 1263-1269
- ⁴⁴ Sell S, Reese D, Ossowski V: Evidence for insulin regulation of alternative splicing of insulin-receptor ore-mRNA. *Diabetes*, 1994; 43: Suppl 1, 176A
- ⁴⁵ Kosaki A, Webster NJ: Effect of dexamethasone on the alternative splicing of the insulin receptor mRNA and insulin action in Hep62 hepatoma cells. *J Biol Chem*, 1993; 268: 21990-21996
- ⁴⁶ Carrascosa JM, Vogt B, Ullrich A, Häring HU: Activation of phosphatidylinositol-3-kinase by insulin is mediated by both A and B human insulin receptor types. *Biochem Biophys Res Commun*, 1991; 174: 123-127
- ⁴⁷ Mühlhöfer A, Kellerer M, Berti L et al.: Characterization of IRS-1 interaction with both insulin receptor isoforms. *Exp Clin Endocrinol*, 1993; 101: Suppl.2 125
- ⁴⁸ Simpson IA, Hedo JA, Cushman SW: Insulin induced internalisation of the insulin receptor in the isolated rat adipose cell: detection of both major receptor subunits following their biosynthetic labelling in culture. *Diabetes*, 1984; 33: 13-18
- ⁴⁹ Knutson VP, Ronnett GV, Lane MD: Rapid reversible internalization of cell surface insulin receptors. Correlation with insulin induced down-regulation. *J Biolol Chem*, 1983; 258: 12139-12142

- ⁵⁰ Hedo JA, Kahn CR, Hayashi M, Yamada KM, Kasuga M: Biosynthesis and glycosylation of the insulin receptor. Evidence for a single polypeptide precursor of the two major subunits. *J Biol Chem*, 1983; 258: 10020-10026
- ⁵¹ Kasuga M, Kahn CR, Hedo JA, Van Obberghen E, Yamada KM: Insulin-induced receptor loss in cultured lymphocytes is due to accelerated receptor degradation. *Proc Natl Acad Sci*, 1981; 78: 6917-6921
- ⁵² Gavin JR, Roth J, Neville DM Jr, DeMeyts P, Buell DN: Insulin-dependent regulation of insulin-receptor concentration. *Proc Natl Acad Sci*, 1974; 71: 84-88
- ⁵³ Preuß P, Will S, Löffler C, Schreiber S, Nikolaus S, Lochs H, Jehle P, Koop I: Regulation of pro- and conrainflammatory cytokines during hypoglycemia *Diabetes*, 1997; 46 (Suppl. 1) 296A
- ⁵⁴ Fiorentino DF, Bond MW, Mosmann TR: Two types of mouse helper T cell. IV. Th2 clones secrete a factor that inhibit cytokine production by Th1 clones. *J Exp Med*, 1989; 170: 2081-2095
- ⁵⁵ Suda T, O'Garra A, MacNeil I: Identification of a novel thymocyte growth promoting factor derived from B cell lymphomas. *Cell Immunol*, 1990; 129: 228-240
- ⁵⁶ Vieira P, de Waal-Malefyt R, Dang MN et al.: Isolation and expression of human cytokine synthesis inhibitory factor (CSIF/IL10) cDNA clones : Homology to Epstein-Barr virus open reading frame BCRFI. *Proc Natl Acad Sci*, 1991; 88: 1172-1176
- ⁵⁷ Meager A: Interleukins. in *Encyclopedia of Molecular Biology*, edited by Meyers RA, 1996; VCH Verlagsgesellschaft mbH, Weinheim, New York, Basel;S.336
- ⁵⁸ Mosmann TR: Properties and functions of interleukin-10. *Adv Immunol*, 1994; 56: 1-26
- ⁵⁹ Howard M, O'Garra A: Biological properties of IL-10. *Immunol Today*, 1992; 13: 198-200

- ⁶⁰ Moore KW, O'Garra A, Malefyt DW, Vieira P, Mosmann TR: Interleukin-10. *Ann Rev Immunol*, 1993; 11: 165-190
- ⁶¹ Moore KW, Mosmann TR: Interleukin 10. *Encyclopedia of Immunology*, edited by Roitt IM, Delvers PJ, 1992; Academic Press, London, San Diego, S.925-927
- ⁶² van Deventer SJH, van der Poll T: Interleukin 10: A Cytokine with multiple anti-inflammatory and some proinflammatory activities. *Cytokine Inhibitors*, edited by Ciliberto G, Savino R, 2001; New York
- ⁶³ Lüderitz O, Galanos C, Rietschel ET: Endotoxins of gram-negative bacteria. *Pharmacol Ther*, 1982; 15: 383-402
- ⁶⁴ Vogel SN: The LPS gene. in: *Tumor necrosis factor. The molecules and their emerging role in medicine*. Edited by Beutler B 1992, Raven Press, Ltd, New York, S. 485-513
- ⁶⁵ van der Poll T, Barber AE, Coyle SM, Lowry SF: Hypercortisolemia increases plasma Interleukin-10 concentrations during human endotoxemia. *J Clin Endocrinol Metab*, 1996; 81: 3604-3606
- ⁶⁶ van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF: Epinephrine inhibits tumour necrosis factor- α and potentiates Interleukin 10 production during human endotoxemia. *J Clin Invest*, 1996; 97: 713-719
- ⁶⁷ Siegmund B, Eigler A, Hartmann G, Hacker U, Endres S: Adrenaline enhances LPS-induced IL10 synthesis: evidence for protein kinase A mediated pathway. *Int J Immunopharmacol*, 1998; 20: 57-69
- ⁶⁸ Carswell EA, Old LJ, Kassel RL, Green S, Flore N, Williamsen B: An endotoxin-induced serum factor that causes necrosis of tumours. *Proc Natl Acad Sci*, 1975; 72: 3666-3670

- ⁶⁹ Beutler B, Greenwald D, Hulmes JD et al.: Identity of tumour necrosis factor and the macrophage secreted factor cachectin. *Nature*, 1985; 316: 552-554
- ⁷⁰ Pennica D, Nedwin GE, Hayflick JS et al.: Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. *Nature*, 1984; 312: 724-729
- ⁷¹ Eck MJ, Beutler B, Kuo G, Merryweather JP, Sprang SR: Crystallization of trimeric recombinant human tumour necrosis factor (cachectin). *J Biol Chem*, 1988; 263: 12816-12819
- ⁷² Hakoshima T, Tomita K: Crystallization and preliminary X-ray investigation reveals that tumour necrosis factor is a compact trimer furnished with 3-fold symmetry. *J Mol Biol*, 1988; 201: 455-457
- ⁷³ Tartaglia LA, Goeddel DV: Two TNF receptors. *Immunol Today*, 1992; 13: 151-153
- ⁷⁴ Tracey KJ, Cerami A: Tumour necrosis factor α . in *Encyclopedia of Immunology*; edited by Roitt IM, Delves PJ; 1992; Academic Press; London; San Diego
- ⁷⁵ Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA Jr: Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factor. *J Immunol*, 1985; 135: 2069-2073
- ⁷⁶ Dinarello CA, Cannon JG, Wolff SM et al.: Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. *J Exp Med*, 1986; 163: 1433-1450
- ⁷⁷ Darlington GJ, Wilson DR, Lachman LB: Monocyte-conditioned medium, interleukin 1 and tumor necrosis factor stimulate the acute phase proteins in human hepatoma cells in vitro. *J Cell Biol*, 1986; 103: 787-793
- ⁷⁸ Akahane K, Hosoi T, Urabe A, Kawakami M, Takaku F: Effects of recombinant tumor necrosis factor (rhTNF) on normal human and mouse hemopoietic progenitor cells. *Int J Cell Clon*, 1987; 5: 16-26

⁷⁹ Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. *Science*, 1986; 234: 470-474

⁸⁰ Feingold KR, Soued M, Staprans I et al: Effect of tumor necrosis factor (TNF) on lipid metabolism in the diabetic rat. Evidence that inhibition of adipose tissue lipoprotein activity is not required for TNF-induced hyperlipidemia. *J Clin Invest*, 1989; 83: 1116-1121

⁸¹ Feingold KR, Serio MK, Adi S et al.: Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. *Endocrinology*, 1989; 80: 184-190

⁸² Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB: The expression of tumour necrosis factor in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. *J Clin Invest*, 1995; 95: 2111-2119

⁸³ Saghizadeh M, Ong JM, Garvey WT, Henry R, Kern PA: The expression of TNF α by human muscle: relationship to insulin resistance. *J Clin Invest*, 1996; 97: 1111-1116

⁸⁴ Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H: Relation between plasma Tumour Necrosis Factor- α and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. *Arterioscler Thromb Vasc Biol*, 1998; 18: 1199-1202

⁸⁵ Beutler B, Han J, Krays V, Giroir BP: Coordinate regulation of TNF biosynthesis at the levels of transcription and translation. in: *Tumor necrosis factor. The molecules and their emerging role in medicine*. Edited by Beutler B 1992, Raven Press, Ltd, New York, S. 561-574

⁸⁶ Böyum A: Isolation of mononuclear cells and granulocytes from human blood. *Scand J Clin Lab Invest Suppl*, 1968; 97: 77-89

⁸⁷ Schwarz R, Bianco R, Handwerker B, Kahn R: Demonstration that monocytes rather than lymphocytes are the insulinbinding cells in preparations of human peripheral blood mononuclear leukocytes *Proc Nat Acad Sci*, 1975; 72: 474-478

- ⁸⁸ Davis SN, Shavers C, Costa F, Mosqueda-Garcia R: Role of cortisol in the pathogenesis of deficient counterregulation after antecedent hypoglycemia in normal humans. *J Clin Invest*, 1996; 98: 680-691
- ⁸⁹ Brillon DJ, Zheng B, Campbell RG, Matthews DE: Effect of cortisol on energy expenditure and amino acid metabolism in humans. *Am J Physiol*, 1995; 268: E501-E513
- ⁹⁰ Connolly CC, Ivy RE, Adkins-Marshall BA et al.: Counterregulation by epinephrine and glucagons during insulin-induced hypoglycemia in the conscious dog. *Diab Res Clin Pract*, 1996; 31: 45-56
- ⁹¹ Mönnikes H, Koop H, Ehlenz K, Dionysius J, Arnold R: Role of circulating catecholamines in the control of pancreatic polypeptid and gastrin release. *Res Med Exp Berl*, 1989; 189:181-187
- ⁹² Raju B, McGregor VP, Cryer PE: Cortisol elevations comparable to those that occur during hypoglycemia do not cause hypoglycemia-associated automatic failure. *Diabetes*, 2003; 52: 2083-2089
- ⁹³ Koricanac G, IsenovicE, Stojanovic-Susulic V, Miskovic D, Zakula Z, Ribarac-Stepic N: Time dependent effects of dexamethasone on serum insulin level and insulin receptors in rat liver and erythrocytes. *Gen Physiol Biophys*, 2006; 25: 11-24
- ⁹⁴ McDonald AR, Maddux BA, Okabayashi Y et al.: Regulation of insulin-receptor mRNA levels by glucocorticoids. *Diabetes*, 1987; 36: 779-781
- ⁹⁵ Okabayashi Y, Maddux BA, McDonald AR, Logsdon CD, Williams JA, Goldfine ID: Mechanisms of insulin-induced insulin receptor downregulation. Decrease of receptor biosynthesis and mRNA levels. *Diabetes*, 1989; 38: 182-187
- ⁹⁶ Liu CY, Mills SE: Decreased insulin binding to porcine adipocytes in vitro by beta-adrenergic agonists. *J Anim Sci*, 1990; 68: 1603-1608

⁹⁷ Lonroth P, Smith U: β -adrenergic dependent down regulation of insulin binding in rat adipocytes. *Biochem Biophys Res Commun*, 1983; 112: 972

⁹⁸ Lee AD, Hansen PA, Schluter J, Gulve EA, Gao J, Holloszy JO: Effects of epinephrine on insulin-stimulated glucose uptake and GLUT-4 phosphorylation in muscle. *Am J Physiol Cell Physiol*, 1997; 273: C1082-1087

⁹⁹ Hunt DG, Ivy JL: Epinephrine inhibits insulin-stimulated muscle glucose transport. *J Appl Physiol*, 2002; 93: 1638-1643

¹⁰⁰ Kelly CM, Fantus G: Insulin binding in non-insulin-dependent diabetes mellitus is correlated with glycemic control: clinical evidence for abnormal receptor regulation in NIDDM. *Metabolism*, 1995; 44: 506-512

¹⁰¹ Fink RI, Kolterman OG, Griffin J et al.: Mechanisms of insulin resistance in aging. *J Clin Invest*, 1983; 71: 1523-1535

¹⁰² Marchant A, Amraoui Z, Gueydan C, et al.: Methylprednisolon differentially regulates IL 10 and TNF production during murine endotoxaemia. *Clin Exp Immunol*, 1996; 106: 91-96

¹⁰³ Fushimi T, Okayama H, Seki T, Shimura S, Shirato K: Dexamethasone suppressed gene expression and production of interleukin-10 by human peripheral mononuclear cells and monocytes. *Int Arch Allergy Immunol*, 1997; 112:13

¹⁰⁴ Kohka H, Iwagaki H, Yoshino T et al.: Hydrocortisone sodium succinate suppressed production of interleukin-10 by human peripheral blood mononuclear cells: clinical significance. *Acta Med Okayama*, 1999; 53: 55-59

¹⁰⁵ Visser J, Boxel- Dezaire A, Methorst D, Brunt T, de Kloet ER, Nagelkerken L: Differential regulation of IL 10 and IL 12 by glucocorticoids in vitro. *Blood*, 1998; 91: 4255-4264

- ¹⁰⁶ Tabardel Y, Duchateau J, Schmartz D et al.: Corticosteroids increase blood interleukin 10 levels during cardiopulmonary bypass in men. *Surgery*, 1996; 119:76
- ¹⁰⁷ Dandona P, Aljada A, Garg R, Mohanty P: Increase in plasma interleukin 10 following hydrocortison injection. *J Clin Endocrinol Metab*, 1999; 84: 1141-1144
- ¹⁰⁸ de Galan BE, Netea MG, Smits P, van der Meer JWM: Hypoglycaemia downregulates endotoxin-induced production of tumour necrosis factor- α , but does not affect IL-1 β , IL-6, or IL-10. *Cytokine*, 2003; 22: 71-76
- ¹⁰⁹ Hetier E, Ayala J, Bousseau A, Prochiantz A: Modulation of interleukin-1 and tumour necrosis factor expression by beta-adrenergic agonists in mouse ameboid microglial cells. *Exp Brain Res*, 1991; 86: 407-413
- ¹¹⁰ Hu XX, Goldmuntz EA, Brosnan CF: The effect of norepinephrine on endotoxin-mediated macrophage activation. *J Neuroimmunol*, 1991; 31: 35-42
- ¹¹¹ Severn A, Rapson NT, Hunter CA, Liew FY: Regulation of tumour necrosis factor production by adrenaline and beta-adrenergic agonists. *J Immunol*, 1992; 148: 3441-3445
- ¹¹² Monastra G, Secchi EF: Beta-adrenergic receptors in vivo: the adrenaline inhibition of lipopolysaccharide- induced tumour necrosis factor release. *Immunol Lett*, 1993; 38: 127-130
- ¹¹³ Semmler J, Wachtel H, Endres S: The specific type IV phosphodiesterase inhibitor rolipram suppresses tumour necrosis factor- α production by human mononuclear cells. *Int Journal of Immunopharmacology*, 1993; 15: 409-413
- ¹¹⁴ Sinha B, Semmler J, Eisenhut T, Eigler A, Endres S: Enhanced tumour necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination by phosphodiesterase inhibitors and prostanoids. *Eur J Immunol*, 1995 ; 25 : 147-153

- ¹¹⁵ Zinyama RB, Bancroft GJ, Sigola LB: Adrenaline suppression of the macrophage nitric oxide response to lipopolysaccharide is associated with differential regulation of tumour necrosis factor-alpha and interleukin-10. *Immunology*, 2001; 104: 439-446
- ¹¹⁶ Bergmann M, Gornikiewicz A, Sautner T et al.: Attenuation of catecholamine-induced immunosuppression in whole blood from patients with sepsis. *Shock*, 1999; 12: 421-427
- ¹¹⁷ Elenkov IJ, Papanicolaou DA, Wilder RL, Chrousos GP: Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. *Proc Assoc Am Physicians*, 1996; 108: 374-381
- ¹¹⁸ Strackowski M, Kowalska I, Nikolajuk A, Krukowska A, Gorska M: Plasma interleukin-10 concentration is positively correlated to insulin sensitivity in young healthy individuals. *Diabetes Care*, 2005; 28: 2036-2037
- ¹¹⁹ Esposito K, Pontillo A, Giugliano F et al.: Association of low interleukin-10 levels with the metabolic syndrome in obese women. *J Clin Endocrinol Metab*, 2003; 88: 1055-1058
- ¹²⁰ Hotamisligil GS, Narinder SS, Spiegelman BM: Adipose expression of tumour necrosis factor- α : Direct role in obesity-linked insulin resistance. *Science*, 1993; 259: 87-91
- ¹²¹ Hotamisligil GS: The role of TNF α and TNF receptors in obesity and insulin resistance. *J Intern Med*, 1999; 245: 621-625